Temozolomide (TMZ)
Temozolomide (TMZ) is a pharmaceutical drug with 34 clinical trials. Currently 20 active trials ongoing. Historical success rate of 70.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
16
Early Stage
17
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
70.0%
7 of 10 finished
30.0%
3 ended early
20
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Clinical Trials (34)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 34